

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	O. F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/701,536	06/18/2001		Gwong-Jen J. Chang	14114.0332U2 5492	
24197	7590	12/17/2003	,	EXAMINER	
KLARQU	JIST SPAI	RKMAN, LLP	PARKIN, JEFFREY S		
121 SW S	ALMON ST	TREET			
SUITE 16	00			ART UNIT	PAPER NUMBER
PORTLAND, OR 97204				1648	16
			,		• •

DATE MAILED: 12/17/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application N .	Applicant(s)				
	09/701,536	CHANG, GWONG-JEN J.				
Office Action Summary	Examiner	Art Unit				
	Jeffrey S. Parkin, Ph.D.	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>01</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on 21 Ju	ı <u>ly 2003</u> .					
2a) ☐ This action is FINAL . 2b) ☑ This a	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 35-86 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ☒ Claim(s) 35-86 are subject to restriction and/or election requirement. Application Papers 9) □ The specification is objected to by the Examiner. 10) □ The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) □ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. §§ 119 and 120						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. a) The translation of the foreign language provisional application has been received. 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s). 1) Notice of Draftsperson's Patent Drawing Review (PTO-948)						
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)		atent Application (PTO-152)				

Serial No.: 09/701,536 Docket No.: 14114.0332U2
Applicant: Chang, G.-J. Filing Date: 06/18/01

Unity of Invention

Status of the Claims

1. Acknowledgement is hereby made of receipt and entry of the preliminary amendment filed 21 July, 2003, and communication dated 18 September, 2003. Claims 35-37, 44, 45, 48, 49, and 55-58 were amended and new claims 68-86 submitted. Claims 35-86 are pending in the instant application.

35 U.S.C. § 371

5

10

15

20

- 2. This application was filed-under 35-U.S.C. §-371- and-is-subject-to unity of invention practice pursuant to 35 U.S.C. § 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In accordance with 37 C.F.R. § 1.499, applicant(s) is/are required, in response to this action, to elect a single invention to which the claims must be restricted.
 - a. Group I, claim(s) 35-54, and 69, drawn to nucleic acids encoding a flavivirus antigen.
 - b. Group II, claim(s) 55-64, 68, and 77-85, drawn to a method of immunizing a host against flavivirus infection.
 - c. Group III, claim(s) 65, drawn to flavivirus antigen.
- d. Group IV, claim(s) 66 and 67, drawn to methods of detecting flaviviral infections.
 - e. Group V, claim(s) 70 and 71, drawn to subviral particles encoding a flavivirus antigen.
- f. Group VI, claim(s) 72-76, drawn to a method of immunizing a host against flavivirus infection employing subviral particles.
- g. Group VII, claim(s) 86, drawn to flavivirus-specific antibody.

Serial No.: 09/701,536 Applicant: Chang, G.-J.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. The claimed invention fails to make a contribution over the prior art (i.e., see the ISA Chapter I search report). As set forth in the search report, the prior art provides various expression constructs encoding flaviviral antigens. Thus, the presence of a special technical feature is clearly absent.

3. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

Correspondence

4. Correspondence related to this application may be submitted to 15 Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward the following Group 1600 fax number: (703) 872-9306. Any inquiry concerning this communication should be directed 20 to Jeffrey S. Parkin, Ph.D., whose telephone number is (703) 308-The examiner can normally be reached Monday through Thursday from 8:30 AM to 6:00 PM. A message may be left on the examiner's If attempts to reach the examiner are voice mail service. unsuccessful, the examiner's supervisors, Laurie Scheiner or James 25 Housel, can be reached at (703) 308-1122 or (703) respectively. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Respectfully,

5

Jeffrey S. Parkin, Ph.D.

Patent Examiner Art Unit 1648

12 December, 2003